Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HS-201 is a heat shock protein 90 (HSP90)-targeted photosensitizer developed for photodynamic therapy (PDT) in cancer treatment. It consists of a small molecule HSP90 inhibitor chemically linked to verteporfin, a photosensitizer. By exploiting the high expression of HSP90 in cancer cells, HS-201 selectively accumulates in tumors, enabling targeted visualization and photodynamic therapy. Upon activation by near-infrared light, it generates reactive oxygen species (ROS) to destroy tumor cells while minimizing damage to normal tissue.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on HS-201.